Camden Partners Nexus leads Series D funding for eNeura

The Baltimore-based company makes a device to treat migraine headaches.

eNeura's sTMS mini is a portable device to treat headaches.

(Courtesy photo)

eNeura, a Baltimore-based company that makes a device to treat migraines, closed a Series D investment round.
The round was led by Camden Partners Nexus, the Inner Harbor firm’s venture fund focusing on biomedical technology. Also participating were the Abell Foundation, entrepreneur David Oros, Marc Blum, and the Fischell family, who also founded the company. The amount of funding raised in the round was not disclosed.
University of Maryland BioPark–based eNeura makes a device called sTMS mini that sends a magnetic pulse into the brain to treat and prevent migraine headaches in a process known as neuromodulation. It’s seen as a replacement for drugs, according to CEO David Rosen. While the device must be prescribed, it is portable and could be used by patients outside a clinic.
“Neuromodulation is the next great advancement in migraine treatment and prevention and we are pleased to have the opportunity to support eNeura’s commercial efforts to expand sTMS access for patients,”  Jacob Vogelstein, Managing Partner at Camden Partners Nexus, said in a statement.
The company reported receiving FDA clearance for the device in September. Now the company is planning to expand its presence in the commercial market, focusing on headache specialists and neurologists at headache centers in the U.S.

Subscribe to our Newsletters
Technically Media
Connect with companies from the community
New call-to-action